Psilocybin is a prodrug, meaning it does nothing on its own. Once you swallow it, your body strips off a phosphate group and converts it into psilocin, the molecule that actually crosses into the brain and produces psychedelic effects. Psilocin works primarily by activating serotonin receptors, triggering a cascade of changes in brain connectivity, sensory processing, and emotional response that can last several hours.
From Psilocybin to Psilocin
Psilocybin is converted to psilocin through a process called dephosphorylation. Enzymes called alkaline phosphatases, found in your gut and liver, cleave the phosphate group from the psilocybin molecule. This small chemical change makes a big difference: psilocin can cross the blood-brain barrier, while psilocybin largely cannot. The conversion happens quickly. Effects typically begin within 20 to 40 minutes of ingestion and last 3 to 6 hours total.
Serotonin Receptors Are the Primary Target
Once in the brain, psilocin binds to serotonin receptors, especially the 5-HT2A receptor. Brain imaging research using a radioactive tracer that binds to the same receptors has confirmed that the intensity of psychedelic effects correlates directly with how many 5-HT2A receptors psilocin occupies and with psilocin levels in the blood. This receptor is now considered the critical molecular trigger for psilocybin’s psychedelic effects.
Psilocin also has weaker affinity for a few other serotonin receptor subtypes, including 5-HT2C and 5-HT1A. Its affinity for the serotonin transporter (the protein that recycles serotonin back into neurons) is roughly 100 times lower than for 5-HT2A. So while psilocin touches several parts of the serotonin system, the 2A receptor does the heavy lifting.
How Brain Networks Reorganize
The most consistent finding in brain imaging studies is that psilocybin disrupts the default mode network (DMN). The DMN is a set of brain regions that are most active when you’re not focused on the outside world: during daydreaming, self-reflection, rumination, and thinking about the past or future. It plays a central role in your sense of self.
Under psilocybin, connectivity within the DMN drops significantly. Key hubs of the network, particularly in the front and back of the brain’s midline, decouple from each other. At the same time, connectivity between networks that normally operate independently goes up. Brain regions that don’t usually talk to each other start exchanging information. This is sometimes described as increased “brain entropy,” a measure of how unpredictable and flexible brain activity becomes. The brain enters a broader array of dynamic states than it normally cycles through.
This reorganization is thought to underlie many of psilocybin’s subjective effects. The loosening of DMN control may explain experiences of ego dissolution, where the usual sense of a bounded self temporarily fades. The increased cross-talk between networks may explain the unusual sensory blending, novel associations, and sense of interconnectedness that people report. In studies of people with depression, reduced DMN integration has been observed up to three weeks after a single dose.
The Thalamic Filter Opens Up
Your thalamus acts as a relay station, filtering sensory information before it reaches the cortex. It decides, in a sense, what gets through and what gets dampened. Psilocybin disrupts this filtering process. Imaging studies show increased connectivity between the thalamus and sensory areas of the cortex, particularly regions involved in vision and hearing. At the same time, connectivity between the thalamus and the prefrontal cortex (involved in reasoning and executive control) decreases.
The result is a kind of sensory flood. More raw perceptual information reaches the cortex than the brain normally permits, while the top-down control that would ordinarily organize and constrain that information is weakened. This helps explain the vivid visual distortions, intensified colors, geometric patterns, and synesthesia-like experiences that characterize the psychedelic state.
Emotional Processing Shifts
Psilocybin also changes how the brain processes emotions at the level of the amygdala, a region central to threat detection and emotional reactivity. In a study of healthy volunteers, amygdala response to angry faces dropped significantly during the psilocybin experience compared to baseline. Responses to neutral faces remained unchanged, suggesting this isn’t a blanket suppression of the amygdala but a selective dampening of threat-related reactivity.
People who reported more intense subjective experiences also showed greater reductions in amygdala response to fearful faces. This selective blunting of negative emotional reactivity, without numbing the brain’s response to neutral stimuli, is one reason researchers have been interested in psilocybin for conditions like depression and PTSD, where the amygdala tends to be overactive in response to negative cues.
New Connections Grow and Last
Beyond temporarily reshuffling brain activity, psilocybin appears to cause lasting structural changes. A study using two-photon microscopy to track individual neurons in mice found that a single dose of psilocybin led to roughly a 10% increase in both the size and density of dendritic spines in the frontal cortex. Dendritic spines are the small protrusions on neurons where synapses form, so more spines means more potential connections between brain cells.
These structural changes appeared within 24 hours of the dose, which is remarkably fast for neural remodeling. More striking, the increased spine density was still present one month later. The growth was driven by a higher rate of new spine formation rather than a slower rate of spine loss. In the same study, psilocybin also reversed behavioral deficits caused by chronic stress, suggesting the new connections aren’t just structural decoration but functionally meaningful.
This rapid and persistent rewiring in the cortex may explain why therapeutic benefits from psilocybin often outlast the drug’s presence in the body by weeks or months. The psychedelic experience is brief, but the synaptic changes it leaves behind provide a physical substrate for longer-term shifts in mood and cognition.
What Happens in the Body
Psilocybin produces modest, temporary increases in heart rate and blood pressure. Across clinical trials, peak systolic blood pressure typically reaches somewhere between 138 and 155 mmHg, depending on dose, with diastolic values in the 76 to 93 mmHg range. Heart rate generally peaks between 78 and 94 beats per minute. These changes are dose-dependent and resolve as the drug wears off. None of the monitored clinical trials reported the need for medical intervention to manage cardiovascular effects.
For context, a typical resting blood pressure of 120/80 and heart rate of 70 beats per minute might temporarily climb to around 140/87 and 85 beats per minute at a standard dose. That’s comparable to moderate physical exertion.
Doses Used in Research
Early clinical trials dosed psilocybin by body weight, typically 0.2 to 0.4 mg per kilogram. More recent protocols have settled on a fixed dose of 25 mg, which corresponds roughly to the earlier weight-based dose of 0.3 mg/kg. A secondary analysis of prior trial data confirmed that the fixed 25 mg dose produces comparable psychedelic effects to the weight-based approach, simplifying dosing without sacrificing consistency.
The Subjective Experience
Researchers measure the psychological effects of psilocybin using structured questionnaires. The most widely used is the Mystical Experience Questionnaire, which captures four core dimensions: a sense of unity or oneness (both internal and with the external world), deeply felt positive mood, the feeling that time and space have been transcended, and ineffability, the sense that the experience is beyond what words can capture. These aren’t just interesting descriptions. Scores on these measures, particularly the mystical and unity dimensions, have repeatedly predicted the size and durability of therapeutic benefits in depression and addiction trials.
The experience isn’t uniformly positive. Challenging psychological material, including anxiety, confusion, and confrontation with difficult emotions, is common and considered by many researchers to be part of the therapeutic process rather than a side effect to be avoided.